With over 20 years in the pharmaceutical industry, Erhardt brings extensive experience in clinical drug development.
Erhardt is a seasoned pharmaceutical executive with broad global experience in medical, clinical operations and development.
He is a board certified, sub-specialty physician (Pediatric Infectious Diseases) with experience within the pharmaceutical industry across numerous therapeutic areas encompassing all phases of drug development as well as all aspects of medical product support.
His background is complimented by significant organizational design and leadership experience.
Erhardt received his B.A. in Electrical Engineering from Brown University and his M.D. from the State University of New York Health Science Center at Syracuse.
He completed his Pediatric Residency and Chief Residency at North Shore University Hospital/Cornell University Medical College and his Fellowship in Infectious Diseases at the Children's National Medical Center.
In addition, Dr. Erhardt has served as a Staff Fellow at the US Food and Drug Administration. Dr. Erhardt is a Fellow of the American Academy of Pediatrics.
Most recently, Dr. Erhardt was senior vice president, Head of Clinical Development and Operations at Pfizer, Inc. responsible for design, conduct and reporting of Pfizer's global Clinical Development portfolio.
He oversaw Pfizer's Clinical, Clinical Sciences, Clinical Project Management and Study Management functions as well as Pfizer's Internal Phase I Clinical Research units in New Haven and Brussels, Belgium.
In this role, Dr. Erhardt was responsible for all Clinical Development functions for a portfolio of 350 clinical studies across the Cardiovascular, Metabolic Neuroscience, Vaccines, Immunology and Inflammation and Rare Disease therapeutic areas.
Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for Alzheimer's disease and related dementias by targeting tau self-association.
The company's drug discovery platform has identified a pipeline of novel small molecule inhibitors, with preclinical IND-enabling studies in progress for the lead program.
Oligomerix's small molecule approach blocks the formation of all tau aggregates by targeting tau self-association, known as the beginning of the aggregation cascade, whereas other companies have focused on targeting large tau aggregates formed downstream.
The NYC-based company is located at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.
Oligomerix is seeking strategic partners to support the acceleration and advancement of these important programmes.
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Oscotec receives ODD from FDA for Cevidoplenib
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
TELA Bio launches LIQUIFIX for US hernia surgery
BD boosts US syringe production amid healthcare demand
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT
Upgraded Syngene International biologics facility to start operation in 2024
BioXcel Therapeutics secures European patent for method to treat agitation in dementia